Raymond James Financial
MNPR icon

Raymond James Financial’s Monopar Therapeutics MNPR Stock Holding History

Raymond James Financial’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-431
Closed -$15.4K – 6031
2025
Q2 		$15.4K Buy
+431
New +$15.7K ﹤0.01% 5713

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Raymond James Financial's MNPR Position: Q3 2025 in Review

Raymond James Financial sold out of Monopar Therapeutics (MNPR) in Q3 2025, closing a stake of 431 shares — an estimated $15.4K sold.

Raymond James Financial first reported a position in MNPR in Q2 2025 and held it in 1 quarter. The position peaked at $15.4K in Q2 2025. 56 funds tracked by Wall St. Rank hold MNPR as of Q3 2025.

  • Raymond James Financial reported no remaining Monopar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 431 Monopar Therapeutics shares in Q3 2025, an estimated $15.4K.
  • Raymond James Financial first reported a position in Monopar Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Monopar Therapeutics position peaked at $15.4K in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.